.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Unmet Needs in HR-Positive Metastatic Breast Cancer

EP. 1: CDK4/6 Inhibition's Role in HR+ Metastatic Breast Cancer

November 30th 2018

EP. 2: Selecting Agents in CDK4/6 Inhibition for HR+ mBC

November 30th 2018

EP. 3: HR+ mBC: Factors in Selecting CDK4/6 Inhibitions

November 30th 2018

EP. 4: HR+ mBC: Treatment After Progression on CDK4/6 Inhibition

November 30th 2018

EP. 5: Do CDK4/6 Inhibitors Impact Later Therapy in HR+ mBC?

November 30th 2018

EP. 6: PI3K and PARP Inhibitors in HR+ Metastatic Breast Cancer

November 30th 2018

EP. 7: Developments in Chemotherapy for HR+ mBC

November 30th 2018

EP. 8: Optimizing Selection of Chemotherapy for HR+ mBC

November 30th 2018

EP. 9: Tesetaxel: An Oral Taxane for HR+ mBC

November 30th 2018

EP. 10: HR+ mBC: Considering the Data and Potential of Tesetaxel

November 30th 2018

EP. 11: Tesetaxel in Doublet Therapy for HR+ mBC

November 30th 2018

EP. 12: HR+ mBC: Oral Formulations of Docetaxel and Paclitaxel

November 30th 2018